Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buparlisib in Metastatic Triple-Negative Breast Cancer
NCT01790932Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2012
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of buparlisib in triple negative breast cancer (TNBC), sponsored by Dana-Farber Cancer Institute. Started Jun 2012; status: completed.
02
Drugs
buparlisib
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01790932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01790932.